Compare ETHZ & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETHZ | LPCN |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6M | 61.8M |
| IPO Year | N/A | 2011 |
| Metric | ETHZ | LPCN |
|---|---|---|
| Price | $3.54 | $10.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 591.9K | 80.5K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,198,144.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 492.80 |
| 52 Week Low | $1.60 | $2.52 |
| 52 Week High | $24.44 | $12.37 |
| Indicator | ETHZ | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 63.33 |
| Support Level | $2.99 | $2.89 |
| Resistance Level | $5.63 | $10.80 |
| Average True Range (ATR) | 0.26 | 0.81 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 59.57 | 81.66 |
ETHZilla Corporation is a technology company in the decentralized finance industry. It seeks to connect financial institutions, businesses and organizations worldwide by enabling secure, accessible blockchain transactions through Ethereum Network protocol implementations. It generates recurring revenues through various DeFi protocols that improve Ethereum network integrity and security. The group enables the seamless tokenization of traditional assets by bringing them on-chain. Leveraging its proprietary protocol solutions, ETHZilla supports DeFi transactions, asset digitization across various Layer 2 Ethereum networks. The platform is focused on delivering tokenization services, DeFi protocol integrations, blockchain analytics, gateways for converting traditional assets to digital forms.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.